Opinion|Videos|October 14, 2024

Clinical Perspectives from the ARANOTE Trial in Metastatic Hormone-Sensitive Prostate Cancer

Key Takeaways

  • Darolutamide's structure limits blood-brain barrier penetration, reducing central nervous system side effects and improving safety.
  • It effectively delays metastasis and prolongs survival in non-metastatic castration-resistant prostate cancer.
SHOW MORE

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how darolutamide offers potential advantages over other androgen receptor–targeted therapies for metastatic prostate cancer, including its unique molecular structure, favorable safety profile, and efficacy in specific clinical scenarios.

Episodes in this series

Video Content above is prompted by the following:

  • What are some of the benefits of darolutamide over other androgen receptor–targeted therapies?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more